» Articles » PMID: 10942038

Smoking and Parkinson's and Alzheimer's Disease: Review of the Epidemiological Studies

Overview
Journal Behav Brain Res
Date 2000 Aug 15
PMID 10942038
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

The relationship between smoking and neurological diseases has always been controversial. Even the expected association between smoking and increased risk for cerebrovascular disease has been debated for years. It was at the end of the 1980s that smoking became definitively accepted as a risk factor for ischemic stroke. More recently, two other neurological diseases have been studied in relation to smoking: Parkinson's disease (PD) and Alzheimer's disease (AD). Many epidemiological studies have found a highly significant negative association between cigarette smoking and these two neurodegenerative disorders. The risk of AD or PD in nonsmokers has generally been about twice that of smokers. That is, patients with AD or PD are approximately 50% less likely to have smoked cigarettes during their lifetime than are age- and gender-matched controls. Alternatively, cigarette smokers are 50% less likely to have PD or AD than are age- and gender-matched nonsmokers. This statistically significant negative association has been interpreted as suggesting that cigarette smoking exerts an undefined, biologic, neuroprotective influence against the development of PD and AD. A review of all studies that either support or refute this hypothesis is presented separately for PD and AD.

Citing Articles

The double-edged nature of nicotine: toxicities and therapeutic potentials.

Cao Y, Sun J, Wang X, Zhang X, Tian H, Huang L Front Pharmacol. 2024; 15:1427314.

PMID: 39206262 PMC: 11350241. DOI: 10.3389/fphar.2024.1427314.


Beta-Adrenergic Suppression of Neuroinflammation in Treatment of Parkinsonism, with Relevance for Neurodegenerative and Neoplastic Disorders.

Inchiosa Jr M Biomedicines. 2024; 12(8).

PMID: 39200184 PMC: 11351568. DOI: 10.3390/biomedicines12081720.


Neuroprotection of low dose carbon monoxide in Parkinson's disease models commensurate with the reduced risk of Parkinson's among smokers.

Rose K, Zorlu M, Fassini A, Lee H, Cai W, Xue X NPJ Parkinsons Dis. 2024; 10(1):152.

PMID: 39174550 PMC: 11341721. DOI: 10.1038/s41531-024-00763-6.


Clearing the Smoke: What Protects Smokers from Parkinson's Disease?.

Rose K, Schwarzschild M, Gomperts S Mov Disord. 2024; 39(2):267-272.

PMID: 38226487 PMC: 10923097. DOI: 10.1002/mds.29707.


Parkinson's Disease Non-Motor Subtypes Classification in a Group of Slovenian Patients: Actuarial vs. Data-Driven Approach.

Petrijan T, Zmazek J, Menih M J Clin Med. 2023; 12(23).

PMID: 38068486 PMC: 10707127. DOI: 10.3390/jcm12237434.